key: cord-0873197-4n14yeyk authors: Mehta, R. M.; Bansal, S.; Kumar, A.; Thorbole, A.; L, C.; Kalpakam, H. title: Bronchoscopy in COVID19 ARDS patients on mechanical ventilation: a prospective study date: 2021-02-05 journal: nan DOI: 10.1101/2021.02.02.21250362 sha: b5339e90cf35777bb01cca3e22a0562a6b743c33 doc_id: 873197 cord_uid: 4n14yeyk Background: Bronchoscopy has been done sparingly in COVID19 patients due to the risk of aerosol generation, with few reports describing its clinical utility. We describe a large case series of bronchoscopy in mechanically ventilated (MV) COVID-19 patients outlining the procedural, clinical, utilitarian and safety aspects. Methods: Bedside bronchoscopy was performed in suspected or confirmed COVID-19 cases on MV; only positive cases were included in the study. Demographic, clinical, bronchoscopic and laboratory findings were noted and analysed. Results: 98 procedures were performed on 61 patients, mean age of 62.1 years, 51 (83.6%) males. 42 patients (69%) had at least 1 co-morbidity. Major indications for bronchoscopy were new radiographic infiltrates with clinical deterioration, increased endotracheal tube (ETT) secretions and haemorrhagic secretions/hemoptysis. Common findings were copious secretions in 87 (88.8%), purulent in 61%, mucoid in 18%, haemorrhagic in 7% and frothy in 14% cases. Morphologically, hyperaemic airways were seen in 85 (86.7%) cases, ranging from mild (61%) to moderate-severe (39%). On the management front, antibiotics were changed in 31 (31.6%) cases based on bronchoscopic findings. Other significant changes included reduction or stopping of steroids and anticoagulation, fluid, and diuretic adjustment and ETT repositioning. The incidence of bacterial superinfection was also high (54% culture positivity for various bacteria), a significant number (94%) with multi-drug resistant organisms. Fungi were seen in 7 cases (7.1%). Pneumocystis jiroveci was not seen and cytology did not show any viral inclusions. Therapeutic mucus plug removal was done in 30 cases (30.6%), and hemoptysis control in 4% cases. The procedures were safe with no complications, and none of the HCW developed any COVID19 infection. Conclusion: Bronchoscopy in critically ill MV COVID-19 patients contributes on both diagnostic and therapeutic fronts and can significantly influence management decisions. With adequate precautions and standard protocols, it is safe for both HCW and patients. Bronchoscopy in COVID19 patients has been challenging due to the high aerosol-related risk to healthcare workers (HCW). (1,2) Several guidelines exist on bronchoscopic sampling in COVID19 patients. (3) Few reports define detailed clinical aspects, management impact and safety of ICU bronchoscopy in this patient population. This study on bronchoscopy in mechanically ventilated (MV) COVID ARDS (C-ARDS) patients was done in the peak of the COVID pandemic, and describes procedural, clinical, utilitarian and safety aspects of the procedure. Prospective observational study conducted at a tertiary committed COVID care center between August 25 and December 3, 2020. Approval for the study was granted by Institutional Ethics Committee Bio Medical Research Apollo Hospital, Bangalore. The study group included all MV ICU patients with initially proven or later confirmed COVID-19 who underwent bronchoscopy for clinical indications (Table 1) . Bronchoscopy was deferred when any of the following were present; PEEP >10 cm H 2 O, hemodynamic instability, or operator's perception of life-threatening deterioration during the procedure. The following variables were recorded: Demographic and clinical parameters such as age, gender, duration of symptoms prior to hospitalization, presence of co-morbidities [diabetes, hypertension, chronic kidney disease (CKD), ischemic heart disease (IHD)], and duration of ventilatory support prior to procedure. Procedure details included indications, findings, relevant microbiological and cytological tests, and management changes following bronchoscopy. Safety aspects from both the patient and the HCW perspective were also studied. Procedure: Bronchoscopy after informed consent was performed by 3 different operators. A bronchoscopy technician, a respiratory therapist and an ICU nurse were present for every procedure. All health care workers (HCW) used adequate personal protective equipment PPE (P-100 respirator, impermeable coverall, face shield and double layered gloves). All HCW's self-monitored for symptoms for the duration of the study and if symptomatic, a nasopharyngeal swab was taken for COVID-19 RT-PCR. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint The procedure was performed at the bedside in the ICU, which had > 20 air exchanges/hour. Negative pressure isolation rooms were not available. Sedation included midazolam and fentanyl and short-acting neuromuscular blockade with atracurium to prevent any aerosol generating cough. Pre-procedure, FiO2 was increased to 100% for 20 mins. During the bronchoscopy, the ventilator was transiently disconnected for periods less than 1 minute to minimize aerosol generation. A rapid bronchoscopy was done, with close monitoring of SpO2 and vital parameters, with brief in-and-out runs with the bronchoscope as needed. As a safety measure, patients in prone position were maintained in the same position to mitigate procedure related desaturation. Pooled washings (average 80-100 ml from multiple segments) were done in view of the need for multi-segment sampling and concern of desaturation with a larger volume BAL. Samples were collected and analysed for laboratory investigations including the COVID-RT PCR. Statistics: Data was tabulated and analysed using SPSS (ver. 25.0, SPSS Inc). Results were analysed in a descriptive fashion as number and percentages, mean and standard deviation, median and inter quartile range (IQR). 98 procedures were done in 61 MV C-ARDS patients. 41 patients had one bronchoscopy procedure, while 20 patients had repeat procedures, for various indications (Table 1) . Baseline characteristics of the study group including demographic and comorbidity details are mentioned in Table 1 . Of note, 69% patients (42/61) had at least 1 comorbidity, while 3 patients (5%) had a combination of DM with chronic respiratory illness, and 6 patients (10%) had DM with CKD. Median duration from symptom onset to hospitalization was 7 days (IQR; 4-10), symptom onset to MV was 10 days (IQR; 7 -13.2), symptom onset to bronchoscopy was 14 days (IQR; 10-20), MV to bronchoscopy was 2.5 days (IQR; 1-6.5). CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint bronchoscopy during tracheostomy as a combined strategy to facilitate a quick procedure and perform airway evaluation and sampling. ( Table 2 ). The commonest bronchoscopic findings were increased secretions, seen in 87 (88.8%) cases. 53 (61%) had thick purulent secretions, 16 (18.4%) had clear mucoid secretions, 12 (14%) had frothy secretions, and 6 (7%) had haemorrhagic secretions. Airway hyperaemia was seen in 85 cases (87%), of which 52 (61%) was mild, and 33 (39%) had moderate to severe hyperaemia. Mucus plugging was seen in 30 (30.6%) cases, which improved after therapeutic suctioning. Mild bleeding was noted in 4 cases (4.1%). Other findings included suspected bronchiectasis in 5 patients evidenced by easy passage of the scope beyond the 5 th generation bronchus, tracheomalacia in 7 patients, mucosal ulceration in 2 patients, and an incidental polypoidal mass lesion (malignancy) in 1 patient. (Table 2 Silver stain did not show Pneumocystis jiroveci and all samples were negative for acid-fast bacilli. In 1 patient, COVID diagnosis was confirmed on washings RT-PCR, after 2 NP swabs were negative. The cytology showed no evidence of viral inclusions or any other significant abnormality. Histopathologically, biopsies done on 4 abnormal endobronchial lesions showed non-specific inflammation, and the LUL mass biopsy showed atypical carcinoid tumor. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint F. Impact of bronchoscopy: In C-ARDS, clinical worsening with new/increasing infiltrates had several possibilities including primary disease progression, superinfection (bacterial, fungal, other) and non-infectious causes (fluid shifts, atelectasis, pulmonary infarction). There was scant literature to guide management at this point in the pandemic, and lower respiratory tract sampling was limited with a restricted suctioning policy. With clinical deterioration, there was a need to supplement clinical judgement with objective data, which was provided by bronchoscopy. Bronchoscopy impacted management in the following ways (Table 3) : (1) Antibiotics were changed/escalated in 31 (31.6%) cases immediately based on bronchoscopic findings of copious purulent secretions. These were not seen in the ETT prior to bronchoscopy in 40/53 (75.5%) patients with purulent secretions and was a new finding. Since most of these patients (94%) grew multi-drug resistant (MDR) organisms sensitive only to the polymyxin group of antibiotics, we changed our policy to empiric polymyxin antibiotics for any patients suspected of infection on MV. (2) When extensive purulent secretions were seen, corticosteroid dosage was reduced/stopped. (3) Anticoagulation was reduced from intermediate to preventive (equivalent of enoxaparin 40mg twice a day to 40mg once a day) in 6 patients (6%) with haemorrhagic secretions, while it was completely stopped for 2 patients with significant persistent ooze. Iced saline with diluted adrenaline (1:10,000) was used to achieve haemostasis. (4) ETT repositioning done in 15 patients (15.3%) due to close proximity to carina (< 1 cm) especially with a prone-supine protocol in place, considering the possibility of caudal bronchial displacement. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint Our study of bronchoscopy in MV COVID-19 critically ill patients describes diagnostic and therapeutic aspects, including morphological details, microbiological and pathological aspects, and procedural and safety aspects. Bronchoscopy helped obtain more information to guide management when there was limited information in a new pandemic. A fundamental limitation in the MV-CARDS patients during the pandemic was restricted suctioning due to aerosol risk, limiting many aspects of diagnosis Table 5 . Our study bears similarities and also contrasts with prior COVID19 bronchoscopy reports. reported diffuse, white, and jelly-like secretions, difficult to suction in 95% patients. (4) The therapeutic aspect of the procedure also has been highlighted in literature. In the above series, in 12 cases, muco-hematic plugs were removed using saline and a mucolytic agent. Bruyneel et al. report that purulent plugs were removed in 33 procedures (37% cases). They further report that "in the majority of these patients, very thick and dry plugs (like limestone) were stuck in the ETT. The tube became quickly dirty and needed to be replaced more often than usual". (5) We had different observations -therapeutic suctioning of thick mucus plugs were done in 30 (30.6%), and only 14 (14.2%) of these had very thick inspissated obstructive secretions. Though we had 1 case where the ETT was almost completely blocked and had to be replaced, we did not commonly face this due to a robust humidification strategy and a strategy of early bronchoscopy if secretion related issues were suspected. With limited suctioning in the active disease phase, the dual role of bronchoscopy as a lower respiratory tract sampling modality and airway de-obstruction therapeutic tool was invaluable. Another interesting observation in our study was hyperaemic and inflamed bronchial mucosa is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint suspicion of infection, was also part of a course correction as we analysed our preliminary culture results. Other important decisions coinciding with antibiotic escalation were to de-escalate/stop corticosteroids when copious purulent secretions were noted, as a systematic immunosuppression reduction strategy. Anticoagulants were reduced when the mucosa was too hyperaemic and bleeding on touch and discontinued in cases of visibly bloody secretions or a persistent ooze, especially in patients with hemoptysis. In terms of fluid management, fluids were reduced, and diuretics introduced in patients with evident pulmonary edema ("frothy secretions") (12%). Hydration and humidification were enhanced with a visibly dry mucosa and inspissated secretions in 5 patients. These findings and consequent management adjustments were possible only with bronchoscopic evaluation. Histopathological evaluation of an incidental mass noted showed atypical carcinoid and the 4 other bronchial biopsies of abnormally inflamed areas showed non-specific inflammation. There were no complications in the biopsy process. For hemoptysis and haemorrhagic secretion management, bleeding control was done with local measures, combined with reduction/cessation of anticoagulation in 8 patients. Our procedure technique factored in both patient and HCW safety and was like that reported earlier, namely pre-oxygenation with 100% FiO2, a quick procedure and scope removal followed by reinsertion in case of desaturation. We additionally interrupted ventilation for brief periods while performing bronchoscopy to minimize aerosol generation. (10) Bronchoscopy in COVID-19 patients when done with adequate precautions is relatively safe with low risk to HCWs. This fact is reinforced in various studies (11, 12) Unique aspects of our study include the value of additional information obtained from bronchoscopy that influenced clinical management, especially in patients where there were . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint no ETT secretions, and limited suctioning as per protocol. Numerous management changes, and antibiotic policy changes done midway were based on information from the procedure. The technique and enhanced PPE (3M respirator with P100 filter) ensured safety both for the patient and the HCW despite the absence of negative pressure. This is one of the few studies with uniform steroid use in C-ARDS, and bronchoscopy helped to define both the microbiological impact of a uniform steroid strategy as well as the decision to continue steroids. In addition, we looked for and did not see any additional mucormycosis, tuberculosis or PJP. Our study has certain limitations -it is restricted to critically ill MV patients at various durations of C-ARDS and represents the sickest end of the spectrum. We could not do molecular studies and were not able to do galactomannan in all the samples. Our sample is typically pooled washings from multiple areas with net volumes 80-100 ml, as these patients were significantly hypoxemic, and a larger volume BAL was perceived as a potential unsafe risk in this critically ill MV cohort. We preferred bronchoscopy to mini-BAL due to the expanded diagnostic and therapeutic role of conventional bronchoscopy as mentioned above. Our study of bronchoscopy in critically ill MV COVID19 patients is one of the few reports which describes the utility and safety of bronchoscopy in this cohort at the peak of the pandemic. Important morphological, microbiological, and pathological data was obtained with reasonable safety for both HCW's and patients. Bronchoscopic intervention was valuable on diagnostic, therapeutic and management altering fronts. It should be strongly considered as a useful and safe modality to enhance effective treatment of these critically ill patients at the point of unexplained clinical deterioration. We like to thank Dr. Michael Cutaia and Dr. Mohammed Munavvar for reviewing the manuscript and providing inputs. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 5, 2021. Anticoagulants stopped 2 2% . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint Characterization of Experimental and Clinical Bioaerosol Generation During Potential Aerosol-Generating Procedures Summarizing societal guidelines regarding bronchoscopy during the COVID 19 pandemic Bronchoscopy in Patients with COVID-19 with Invasive Mechanical Ventilation: A Single-Center Experience Bronchoscopy in COVID 19 intensive care unit patients Bronchoalveolar Lavage in COVID-19 Patients with Invasive Mechanical Ventilation for ARDS COVID 19 associated pulmonary aspergillosis COVID-19-associated Pulmonary Aspergillosis SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience Airborne precautions recommended in Wuhan, China for bedside fiberoptic bronchoscopy examination of patients with COVID-19 Bronchoscopy on Intubated COVID-19 Patients is Associated with Low Infectious Risk to Operators Bronchoscopy in children with COVID 19: A case series . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250362 doi: medRxiv preprint